232 related articles for article (PubMed ID: 29857523)
1. Extension of Tissue Plasminogen Activator Treatment Window by Granulocyte-Colony Stimulating Factor in a Thromboembolic Rat Model of Stroke.
Dela Peña IC; Yang S; Shen G; Fang Liang H; Solak S; Borlongan CV
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29857523
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis.
dela Peña IC; Yoo A; Tajiri N; Acosta SA; Ji X; Kaneko Y; Borlongan CV
J Cereb Blood Flow Metab; 2015 Feb; 35(2):338-46. PubMed ID: 25425079
[TBL] [Abstract][Full Text] [Related]
3. Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke.
Gautier S; Ouk T; Tagzirt M; Lefebvre C; Laprais M; Pétrault O; Dupont A; Leys D; Bordet R
J Neuroinflammation; 2014 May; 11():96. PubMed ID: 24885160
[TBL] [Abstract][Full Text] [Related]
4. Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke.
Wang Z; Shan W; Cao J; Wintermark M; Huang W; Zuo Z
J Neurosci Res; 2018 Mar; 96(3):449-458. PubMed ID: 28976017
[TBL] [Abstract][Full Text] [Related]
5. IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.
Zuo W; Chen J; Zhang S; Tang J; Liu H; Zhang D; Chen N
Eur J Neurosci; 2014 Jun; 39(12):2107-18. PubMed ID: 24649933
[TBL] [Abstract][Full Text] [Related]
6. Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Nakano T; Irie K; Hayakawa K; Sano K; Nakamura Y; Tanaka M; Yamashita Y; Satho T; Fujioka M; Muroi C; Matsuo K; Ishikura H; Futagami K; Mishima K
Brain Res; 2015 Oct; 1624():330-335. PubMed ID: 26254727
[TBL] [Abstract][Full Text] [Related]
7. Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.
Jiang Y; Fan X; Yu Z; Cheng C; Wang XS; Lo EH; Sun X; Wang X
Neurosci Lett; 2015 Aug; 602():73-8. PubMed ID: 26149229
[TBL] [Abstract][Full Text] [Related]
8. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
[TBL] [Abstract][Full Text] [Related]
9. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke.
Kano T; Katayama Y; Tejima E; Lo EH
Brain Res; 2000 Jan; 854(1-2):245-8. PubMed ID: 10784130
[TBL] [Abstract][Full Text] [Related]
10. Association of growth factors with arterial recanalization and clinical outcome in patients with ischemic stroke treated with tPA.
Sobrino T; Millán M; Castellanos M; Blanco M; Brea D; Dorado L; Rodríguez-González R; Rodríguez-Yáñez M; Serena J; Leira R; Dávalos A; Castillo J
J Thromb Haemost; 2010 Jul; 8(7):1567-74. PubMed ID: 20456746
[TBL] [Abstract][Full Text] [Related]
11. Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
García-Culebras A; Palma-Tortosa S; Moraga A; García-Yébenes I; Durán-Laforet V; Cuartero MI; de la Parra J; Barrios-Muñoz AL; Díaz-Guzmán J; Pradillo JM; Moro MA; Lizasoain I
Stroke; 2017 Jun; 48(6):1695-1699. PubMed ID: 28428349
[TBL] [Abstract][Full Text] [Related]
12. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
13. NURR1 involvement in recombinant tissue-type plasminogen activator treatment complications after ischemic stroke.
Merino-Zamorano C; Hernández-Guillamon M; Jullienne A; Le Béhot A; Bardou I; Parés M; Fernández-Cadenas I; Giralt D; Carrera C; Ribó M; Vivien D; Ali C; Rosell A; Montaner J
Stroke; 2015 Feb; 46(2):477-84. PubMed ID: 25503547
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
15. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
[TBL] [Abstract][Full Text] [Related]
16. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Zarisfi M; Allahtavakoli F; Hassanipour M; Khaksari M; Rezazadeh H; Allahtavakoli M; Taghavi MM
Brain Res Bull; 2017 Sep; 134():85-90. PubMed ID: 28710023
[TBL] [Abstract][Full Text] [Related]
17. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Wang L; Fan W; Cai P; Fan M; Zhu X; Dai Y; Sun C; Cheng Y; Zheng P; Zhao BQ
Ann Neurol; 2013 Feb; 73(2):189-98. PubMed ID: 23280993
[TBL] [Abstract][Full Text] [Related]
18. Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
Esmaeeli-Nadimi A; Kennedy D; Allahtavakoli M
Eur J Pharmacol; 2015 Oct; 764():55-62. PubMed ID: 26123846
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive Therapy Approaches for Ischemic Stroke: Innovations to Expand Time Window of Treatment.
Knecht T; Story J; Liu J; Davis W; Borlongan CV; Dela Peña IC
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29257093
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
Lapchak PA; Chapman DF; Zivin JA
Stroke; 2001 Jan; 32(1):147-53. PubMed ID: 11136930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
